z-logo
open-access-imgOpen Access
First seroepidemiological investigation of human enterovirus 71 in Iran
Author(s) -
Mahsa Javadi,
Ahmad Nejati,
Maryam Yousefi,
Mahmood Mahmoodi,
Zabihollah Shoja,
Shohreh Shahmahmoodi
Publication year - 2021
Publication title -
iranian journal of microbiology.
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.37
H-Index - 27
eISSN - 2008-4447
pISSN - 2008-3289
DOI - 10.18502/ijm.v13i4.6975
Subject(s) - medicine , poliovirus , poliomyelitis , antibody , titer , neutralizing antibody , enterovirus , outbreak , enterovirus 71 , virology , antibody titer , immunology , virus
Background and Objectives: Human Enterovirus 71 (EV-A71) is the causative agent for many dermal to neurological diseases especially polio-like paralysis outbreaks around the world. This study, the first of this kind in Iran, aimed to find neu- tralizing antibodies against EV-A71 in serum of healthy individuals in different age groups based on neutralization test (NT). Materials and Methods: In this cross-sectional study, 547 serum samples were collected from healthy individuals who were referring for routine checkup tests (aged from under 6 months to over 31 years old) to Imam-Khomeini Hospital in Tehran during January-December 2015. Serum samples were examined by NT in cell culture to detect neutralizing antibodies against EV-A71. In the next step, some of the positive samples were subjected to complete titration to determine the exact titer of anti-EV-A71 antibodies. Results: Of 547 samples, 310 (56.7%) were positive for EV-A71 neutralizing antibody. The presence of the antibody in- creased with age (p<0.001), and there was a significant statistical relationship between sex and the presence of antibody (p=0.009). Conclusion: Our results demonstrated an apparent but limited circulation of EV-A71 in our society. After the worldwide eradication of poliovirus, EV-A71 which can cause polio-likes syndrome, might be the new challenge for our health care system as regard more in depth research is however needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here